This recent transaction increases Fonds De Solidarité Ftq’s holding in the company by 12% to a total of $21.32 million. This is Ftq’s first transaction since reporting a Buy transaction on MIST back in January 2020
The company has a one-year high of $5.73 and a one-year low of $1.31. Currently, IMV has an average volume of 16.59M.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $5.13, reflecting a -70.8% downside.
Fonds De Solidarité Ftq’s trades have generated a 3.2% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm’s candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck’s Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.